CD274 and non-small cell lung carcinoma: The main goal of this research was to evaluate the clinical significance and predictive value of LIPI as a marker in the prognosis of the treatment outcome in patients with metastatic NSCLC and positive PD-L1 mutation treated with the first-line oncology treatment (immunotherapy or combination of chemotherapy and immunotherapy).